國家衛生研究院 NHRI:Item 3990099045/4334
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 911243      在线人数 : 921
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4334


    题名: Development of EGFR-targeting nanomedicine for effectively and noninvasively treats lung cancer patients by aerosol delivery
    其它题名: World Congress on Medical Physics and Biomedical Engineering: Micro- and Nanosystems in Medicine, Active Implants, Biosensors
    作者: Tseng, CL;Wu, YH;Yu, SW;Yang, KC;Lin, FH
    贡献者: Division of Medical Engineering Research
    摘要: Lung cancer is a harmful form of cancer. The long-term survival rate of lung cancer patients treated by conventional modalities remains far from satisfactory. Encapsulated anticancer drugs in nanocarriers, can protect not only the integrity of drugs during transport but also the normal tissues from the toxicity. To develop an effective drug delivery system for lung cancer therapy, gelatin nanoparticles (GPs) were modified with NeutrAvidin <sup>FITC</sup>-biotinylated epidermal growth factor (bEGF) to form EGF receptor (EGFR)-seeking nanoparticles (GP-Av-bEGF). Cisplatin, a key drug used in the chemotherapy with sever side effect, was incorporated in the nanocarriers for active targeting to reduce toxicity. Furthermore, these nanocarriers were given to mice via inhalation of aerosol droplets which were generated by a nebulizer and delivered to mice model of lung cancer via aerosol. To summarize, the in vivo targeting ability of GP-Av-bEGF was examined by fluorescence images obtained from live mice showed that these nanoparticles could target the cancerous lungs in a more specific manner by aerosol delivery. And gelatin nanoparticles loaded with cisplatin and decorated with EGF tumor-specific ligand (GP-PtbEGF) were also successfully developed. Their in vitro and in vivo targeting ability and anticancer effect were confirmed. This treatment showed that GP-Pt-bEGF had stronger antitumor activity and was less toxic compared with other cisplatin formulas. Furthermore, these formulations were given to mice with lung cancer via aerosol delivery and showed that inhaled GP-Pt-bEGF could target EGFR-overexpressing cells to achieve high cisplatin dosage in cancerous lungs. The aerosol delivery of nanocarriers was demonstrated here. Simple aerosol delivery of targeted drug carriers may prove useful for the clinical treatment of lung cancer patients to eliminate patient complaints associated with the frequent intravenous injection.
    日期: 2009-09
    關聯: IFMBE Proceedings. 2009 Sep;25(8):347-350.
    Link to: http://dx.doi.org/10.1007/978-3-642-03887-7
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000291667000100
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77949903150
    显示于类别:[林峯輝] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    SCP77949903150.pdf745KbAdobe PDF547检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈